PCR-based ordered genomic libraries: a new approach to drug target identification for Streptococcus pneumoniae.
Described here are the development and validation of a novel approach to identify genes encoding drug targets in Streptococcus pneumoniae. The method relies on the use of an ordered genomic library composed of PCR amplicons that were generated under error-prone conditions so as to introduce random mutations into the DNA. Since some of the mutations occur in drug target-encoding genes and subsequently affect the binding of the drug to its respective cellular target, amplicons containing drug targets can be identified as those producing drug-resistant colonies when transformed into S. pneumoniae. Examination of the genetic content of the amplicon giving resistance coupled with bioinformatics and additional genetic approaches could be used to rapidly identify candidate drug target genes. The utility of this approach was verified by using a number of known antibiotics. For drugs with single protein targets, amplicons were identified that rendered S. pneumoniae drug resistant. Assessment of amplicon composition revealed that each of the relevant amplicons contained the gene encoding the known target for the particular drug tested. Fusidic acid-resistant mutants that resulted from the transformation of S. pneumoniae with amplicons containing fusA were further characterized by sequence analysis. A single mutation was found to occur in a region of the S. pneumoniae elongation factor G protein that is analogous to that already implicated in other bacteria as being associated with fusidic acid resistance. Thus, in addition to facilitating the identification of genes encoding drug targets, this method could provide strains that aid future mechanistic studies.
Infectious Disease Research, Lilly Research Laboratories, Eli Lilly and Company, Drop Code 0428, Indianapolis, IN 46285, USA. Belanger_Aimee@Lilly.com
Aimee E
AE
Belanger
Angel
A
Lai
Marcia A
MA
Brackman
Donald J
DJ
LeBlanc
D000900:Anti-Bacterial Agents / Q000138:chemical synthesis* / Q000494:pharmacology*; D019295:Computational Biology; D004269:DNA, Bacterial / Q000235:genetics; D015195:Drug Design; D004353:Drug Evaluation, Preclinical; D004352:Drug Resistance, Microbial / Q000235:genetics; D005672:Fusidic Acid / Q000494:pharmacology; D015723:Gene Library; D009154:Mutation / Q000235:genetics; D020653:Peptide Elongation Factor G / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods*; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000235:genetics*
D000900:Anti-Bacterial Agents; D004269:DNA, Bacterial; D020653:Peptide Elongation Factor G; D005672:Fusidic Acid